Document is current
Any future updates will be listed below
-
Authors
Sierro-Martínez, Belén
Guijarro-Albaladejo, Beatriz
Fernández-Cisnal, Ricardo
Rodríguez-Gil, Alfonso
Hernández-Díaz, Paola
de la Rosa-Garrido, María
Carrasco-Brocal, Inmaculada
Lara-Chica, Maribel
Escamilla-Gómez, Virginia
Muñoz-García, Raquel
Bella, Ángela
García-Cózar, Francisco Jose
Pérez-Simón, Jose Antonio https://orcid.org/0000-0003-3616-6101
García-Guerrero, Estefanía https://orcid.org/0000-0002-3041-9860
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (ICI20/00118, RD21/0017/0021, PI20/01792)
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 15 July 2025
First Online: 19 August 2025
Declarations
:
: Peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats of healthy donors kindly donated by the Regional Centre for Blood Transfusions at Virgen del Rocío University Hospital, Sevilla (Spain) after written informed consent. Leukapheresis from healthy donors were obtained from the leukapheresis unit of the Virgen del Rocío University Hospital, Sevilla (Spain) after written informed consent.
: All authors consent for publication.
: J.A.P.S is an advisor or consultant for Novartis, Janssen, Roche, Jazz Pharmaceuticals, Amgen, and Gilead Sciences; reports research support from Novartis, Janssen, Pfizer, Roche, and Takeda; reports travel support from Roche, Gilead Sciences and Janssen; and reports patents, royalties, or other intellectual property from Entourage Bioscience on cannabinoid derivatives. E.G.G has been a consultant to Cellgene and GLS, and received travel grants and/or speaker fees from Cellgene, Amgen, Janssen. E.G.G is a co-inventor on a patent application on the use of BCMA-CAR T-cell therapy in combination with ATRA, “Combination treatment of BCMA CAR-T and ATRA in multiple myeloma” (WO2021/209498 A1), that has been filed by the University of Würzburg, Würzburg, Germany and licensed to T-CURX GmbH, Würzburg, Germany.
